SCHEMBL6872503

SCHEMBL6872503

O=C1Nc2ncc(-c3ccccc3)cc2/C1=C/Nc1ccc(O)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.41
NTRK1 P04629 3/20 0.37
CHEK1 O14757 2/20 0.37
PRKD3 O94806 2/20 0.37
MAP4K4 O95819 2/20 0.37
RET P07949 2/20 0.37
PIM1 P11309 2/20 0.37
KDR P35968 2/20 0.37
FLT3 P36888 2/20 0.37
CDK8 P49336 2/20 0.37
GSK3A P49840 2/20 0.37
GSK3B P49841 2/20 0.37
RPS6KA3 P51812 2/20 0.37
LIMK1 P53667 2/20 0.37
CDK5 Q00535 2/20 0.37
MAP4K2 Q12851 2/20 0.37
LRRK2 Q5S007 2/20 0.37
AURKB Q96GD4 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6872505 1.00 JAK3 (0.41) JAK3NTRK1CHEK1PRKD3MAP4K4
SCHEMBL6884628 0.88 KDR (0.36) JAK3CHEK1KDRCDK8MET
SCHEMBL6884634 0.88 KDR (0.36) JAK3CHEK1KDRCDK8MET
SCHEMBL7733049 0.87 CDC25B (0.41) JAK3NTRK1PIM1MAP3K11RAF1
SCHEMBL7733054 0.87 CDC25B (0.41) JAK3NTRK1PIM1MAP3K11RAF1
SCHEMBL6882587 0.86 AXL (0.35) JAK3NTRK1CHEK1PRKD3MAP4K4
SCHEMBL6882591 0.86 AXL (0.35) JAK3NTRK1CHEK1PRKD3MAP4K4
SCHEMBL6882028 0.86 NTRK1 (0.46) JAK3NTRK1FLT3GSK3BRAF1
SCHEMBL6882023 0.86 NTRK1 (0.46) JAK3NTRK1FLT3GSK3BRAF1
SCHEMBL6882552 0.81 RAF1 (0.47) NTRK1CHEK1FLT3GSK3BAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX JAK3 173/4885NTRK1 1095/4885CHEK1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.